Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 20/20 | 0.55 |
| ▸ | PPARA | Q07869 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | GMNN | O75496 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | TACR2 | P21452 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2786254 | 1.00 | PPARG (0.55) | PPARGPPARAMEN1GMNNEGFR | |
| SCHEMBL6636947 | 0.93 | PPARG (0.64) | PPARGPPARA | |
| SCHEMBL2788955 | 0.93 | PPARG (0.64) | PPARGPPARA | |
| SCHEMBL6635105 | 0.83 | PPARG (0.61) | PPARGPPARAMEN1GMNNEGFR | |
| SCHEMBL6679623 | 0.83 | PPARG (0.61) | PPARGPPARAMEN1GMNNEGFR | |
| SCHEMBL6636438 | 0.82 | PPARG (0.58) | PPARGPPARA | |
| SCHEMBL6637185 | 0.82 | PPARG (0.58) | PPARGPPARA | |
| SCHEMBL2785308 | 0.82 | PPARG (0.58) | PPARGPPARA | |
| SCHEMBL4644281 | 0.78 | PPARG (0.68) | PPARGPPARA | |
| SCHEMBL4644288 | 0.78 | PPARG (0.68) | PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1414806-A1 | NOVEL VINYL N-(2-BENZOYLPHENYL)-L-TYROSINE DERIVATIVES AND THEIR USE AS ANTIDIABETICS ETC | NOVO NORDISK A/S (DK) | 2004-05-06 | — | — | EP | claimed |
| US-20030055076-A1 | Novel compounds, their preparation and use | NOVO NORDISK A/S (DK) | 2003-03-20 | — | — | US | claimed |
| WO-2003011834-A1 | NOVEL VINYL N-(2-BENZOYLPHENYL)-L-TYROSINE DERIVATIVES AND THEIR USE AS ANTIDIABETICS ETC | NOVO NORDISK A/S (DK) | 2003-02-13 | — | — | WO | claimed |
| EP-1414806-A1 | NOVEL VINYL N-(2-BENZOYLPHENYL)-L-TYROSINE DERIVATIVES AND THEIR USE AS ANTIDIABETICS ETC | NOVO NORDISK A/S (DK) | 2004-05-06 | — | — | EP | disclosed |
| US-20030055076-A1 | Novel compounds, their preparation and use | NOVO NORDISK A/S (DK) | 2003-03-20 | — | — | US | disclosed |
| WO-2003011834-A1 | NOVEL VINYL N-(2-BENZOYLPHENYL)-L-TYROSINE DERIVATIVES AND THEIR USE AS ANTIDIABETICS ETC | NOVO NORDISK A/S (DK) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055076-A1 | Novel compounds, their preparation and use | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885MEN1 4829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.